Cell3 Target: Whole Exome Enrichment
Optimize your sequencing efficiency with our Cell3 Target: Whole Exome Enrichment panel.
By capturing 33 Mb of highly-conserved protein-coding regions and 99% of ClinVar variants, you can focus on the most relevant genomic content while reducing sequencing costs.
Cell3 Direct: Fetal RhD Genotyping
The first ‘direct from plasma’ non-invasive prenatal test for fetal Rhesus D (RhD) genotyping. With no cffDNA extraction required, Cell3 Direct reduces costs and saves time in fetal Rhesus D diagnosis. Targeting sequences specific for exons 5, 7 and 10 of the RhD gene, this kit can distinguish between RhD positive, negative and Psi genotypes in cffDNA.
Cell3 Target: Nexome
Maximize your coverage of clinically relevant targets in coding, and non-coding regions. with our Cell3 Target: Nexome panel.
Validate and run one workflow for all variants including SNVs, INDELs and CNVs in a single, clinical-grade assay with this enhanced whole exome panel. No matter how challenging, Cell3 Target: Nexome is validated with all DNA types (gDNA, FFPE DNA, cfDNA (cffDNA)).
GALEAS™ HereditaryPlus
A comprehensive hereditary cancer test with tailored bioinformatics offering a viable option for reducing MLPA.
An expertly curated NGS panel design with coverage of 146 genes with known associations in inherited cancer, GALEAS HereditaryPlus offers full coverage of the UK National Genomics Test Directory and compliant with ESMO/AMP guidelines.
Nonacus has an extensive publication portfolio that supports our innovative solutions in genetic and genomic analysis. We are proud to share our contributions and latest research findings with the scientific community. Our publications range from non-invasive prenatal testing (NIPT) to cancer genomic analysis and make significant contributions to scientific progress. Below, you can explore our latest research and studies.